Use of Native Peptides and Their Optimized Derivatives For Vaccination

Abstract

The present invention pertains to the field of vaccination, and more particularly to the fields of antitumor and antiviral vaccination. The invention relates to the use of a native peptide in a medicinal composition, for selecting and/or boosting part of a CTL immune response which has been initiated by an optimized immunogenic peptide derived from said native peptide. The invention also concerns vaccination kits which comprise several doses of optimized peptides and of their cognate native peptides.

1 . A vaccination kit, comprising at least one dose of a native peptide and at least one dose of an optimized immunogenic peptide derived from said native peptide, wherein said native and optimized peptides are selected from the group consisting of the following pairs of peptides:
 TERT572 (SEQ ID No: 1) and TERT572Y1 (SEQ ID No: 2);   TERT988 (SEQ ID No: 3) and TERT988Y1 (SEQ ID No: 4);   MAGE-A248D9 (SEQ ID No: 5) and MAGE-A248V9 (SEQ ID No: 6);   MAGE-A248G9 (SEQ ID No: 7) and MAGE-A248V9 (SEQ ID No: 6);   Gp100 154 (SEQ ID No: 8) and Gp100 154Y1 (SEQ ID No: 9);   Gp100 154 (SEQ ID No: 8) and Gp100 154M155 (SEQ ID No: 10);   FluM58 (SEQ ID No: 11) and FluM58Y1 (SEQ ID No: 12);   HIVgag76 (SEQ ID No: 13) and HIVgag76Y1 (SEQ ID No: 14);   HBVpol575 (SEQ ID No: 15) and HBVpol575Y1 (SEQ ID No: 16);   HBVpol765 (SEQ ID No: 17) and HBVpol765Y1 (SEQ ID No: 18);   Mart-127 (SEQ ID No: 19) and Mart-127Y1 (SEQ ID No: 20);   Mart-126 (SEQ ID No: 21) and Mart-126L27 (SEQ ID No: 22);   Gp100 177 (SEQ ID No: 23) and Gp100 177Y1 (SEQ ID No: 24);   Gp100 178 (SEQ ID No: 25) and Gp100 178Y1 (SEQ ID No: 26);   Gp100 570 (SEQ ID No: 27) and Gp100 570Y1 (SEQ ID No: 28);   Gp100 209 (SEQ ID No: 29) and Gp100 209Y1 (SEQ ID No: 30);   Gp100 209 (SEQ ID No: 29) and Gp100 209M210 (SEQ ID No: 31);   Gp100 476 (SEQ ID No: 32) and Gp100 476Y1 (SEQ ID No: 33);   Gp100 457 (SEQ ID No: 34) and Gp100 457Y1 (SEQ ID No: 35);   HER-2/neu799 (SEQ ID No: 36) and HER-2/neu799Y1 (SEQ ID No: 37);   HER-2/neu369 (SEQ ID No: 38) and HER-2/neu369Y1 (SEQ ID No: 39);   HER-2/neu789 (SEQ ID No: 40) and HER-2/neu789Y1 (SEQ ID No: 41);   HER-2/neu48 (SEQ ID No: 42) and HER-2/neu48Y1 (SEQ ID No: 43);   HER-2/neu773 (SEQ ID No: 44) and HER-2/neu773Y1 (SEQ ID No: 45);   HER-2/neu5 (SEQ ID No: 46) and HER-2/neu5Y1 (SEQ ID No: 47);   HER-2/neu851 (SEQ ID No: 48) and HER-2/neu851Y1 (SEQ ID No: 49);   HER-2/neu661 (SEQ ID No: 50) and HER-2/neu661Y1 (SEQ ID No: 51);   HER-2/neu650 (SEQ ID No: 52) and HER-2/neu650Y1 (SEQ ID No: 53);   HER-2/neu466 (SEQ ID No: 54) and HER-2/neu466Y1 (SEQ ID No: 55);   HER-2/neu402 (SEQ ID No: 56) and HER-2/neu402Y1 (SEQ ID No: 57);   HER-2/neu391 (SEQ ID No: 58) and HER-2/neu391Y1 (SEQ ID No: 59);   HER-2/neu971 (SEQ ID No: 60) and HER-2/neu971Y1 (SEQ ID No: 61);   HBVpol28 (SEQ ID No: 62) and HBVpol28Y1 (SEQ ID No: 63);   HBVpol594 (SEQ ID No: 64) and HBVpol594Y1 (SEQ ID No: 65);   HBVpol985 (SEQ ID No: 66) and HBVpol985Y1 (SEQ ID No: 67);   EphA2 61 (SEQ ID No: 68) and EphA2 61Y1 (SEQ ID No: 69);   HER2 911 (SEQ ID No: 70) and HER911Y1V10 (SEQ ID No: 71);   HER4 911 (SEQ ID No: 72) and HER911Y1V10 (SEQ ID No: 71);   HER1 911 (SEQ ID No: 73) and HER911Y1V10 (SEQ ID No: 71);   HER2 722 (SEQ ID No: 74) and HER722Y1V9 (SEQ ID No: 75);   HER3 722 (SEQ ID No: 76) and HER722Y1V9 (SEQ ID No: 75);   HER4 722 (SEQ ID No: 77) and HER722Y1V9 (SEQ ID No: 75);   HER1 722 (SEQ ID No: 78) and HER722Y1V9 (SEQ ID No: 75);   HER2 845 (SEQ ID No: 79) and HER845Y1 (SEQ ID No: 80);   HER3 845 (SEQ ID No: 81) and HER845Y1 (SEQ ID No: 80);   HER2 904 (SEQ ID No: 82) and HER904Y1 (SEQ ID No: 83);   HER4 904 (SEQ ID No: 84) and HER904Y1 (SEQ ID No: 83);   HER2 933 (SEQ ID No: 85) and HER933Y1 (SEQ ID No: 86);   HER1 933 (SEQ ID No: 87) and HER933Y1 (SEQ ID No: 86);   HER2 945 (SEQ ID No: 88) and HER945Y1 (SEQ ID No: 90);   HER3 945 (SEQ ID No: 89) and HER945Y1 (SEQ ID No: 90);   HER4 945 (SEQ ID No: 91) and HER945Y1 (SEQ ID No: 90); and   HER1 945 (SEQ ID No: 92) and HER945Y1 (SEQ ID No: 90), and   wherein said vaccination kit further comprises a notice of use indicating that the kit is intended for performing a method of vaccinating a patient against a tumoral or viral antigen comprising a first step of vaccination with an optimized peptide cognate to a native peptide of said antigen, followed by a second step of vaccination with said native peptide, whereby the step of vaccination with the native peptide amplifies CTLs with high avidity for said native peptide.   
     
     
         2 . The vaccination kit of  claim 1 , which comprises 2 or 3 doses of optimized peptide, and 3, 4, 5, 6 or up to 50 doses of native peptide. 
     
     
         3 . The vaccination kit of  claim 1 , wherein each dose comprises 1 to 5 mg of peptide. 
     
     
         4 . The vaccination kit of  claim 1 , wherein said vaccination doses are formulated for subcutaneous injection. 
     
     
         5 . The vaccination kit of  claim 1 , wherein said vaccination doses are formulated for a human patient. 
     
     
         6 . The vaccination kit of  claim 1 , wherein said native peptide is from a tumor antigen. 
     
     
         7 . The vaccination kit of  claim 1 , wherein said native peptide is from a viral antigen.